TABLE 2.
Adjuvant Therapies After LT for HCC: Prospective Randomized Controlled Trials
| Study | Treatment | Treated Patients/ Controls (n/n) | Follow-Up (Years) | Disease-Free Survival: Treated Patients/ Controls (%/%) | Overall Survival: Treated Patients/ Controls (%/%) | Results | Level of Evidence |
|---|---|---|---|---|---|---|---|
| Söderdahl et al.18 (2006) | Doxorubicin: 10 mg/m2 weekly before and after LT and 15 mg/m2 during LT for a maximum cumulative dose of 400 mg/m2 | 19/27 | 3 | 63/50 (P = NS) | 63/70 (P = NS) | No statistical improvement* | 2b |
| Pokorny et al.19 (2005) | Doxorubicin: 15 mg/m2 biweekly before, during, and after LT for a cumulative LT dose of 300 mg/m2 | 34/28 | 5 | 43/53 (P = NS) | 38/40 (P = NS) | No impact of adjuvant therapy on disease-free or overall survival | 2b |
| Xu et al.20 (2007) | Licartin: 15.4 MBq/kg monthly for 3 months | 30/30 | 1 | 57.1/26.7 (P = 0.017) | 82.5/61.9 (P = 0.028) | Reduced recurrence and increased survival with Licartin | 2b |
| Li et al.21 (2007) | Epirubicin after LT with or without thymidine kinase to the peritoneum during LT | 23/22 | 3 | 43.5/9.1 (P = 0.001) | 69.6/19.6 (P = 0.001) | Reduced recurrence | 2b |
*
The study was stopped early because of a lack of demonstrated benefits.